The author of this report describes a pragmatic therapeutic approach that can be administered to an adolescent receiving dialectical behavior therapy, who may perceive certain steps in therapy as burdensome and subsequently drop out of treatment.
Borderline personality disorder (BPD) is thought to lead to poor response to electroconvulsive therapy (ECT) in depressed patients. This study assessed symptom-severity outcomes among depressed patients with and without comorbid BPD who received ECT.
Most evidence-based treatments for borderline personality disorder (BPD) are prohibitively lengthy and intensive. This study explores a psychoeducational group intervention as a possible treatment alternative for this underserved patient group.
Associations between depression, personality traits, and emotions are complex and reciprocal. This study explored these interactions in a patient sample by applying a new method called network analysis. Find out whether these interactions changed depending on the severity of depressive symptoms at 3-month follow-up.
Are some people genetically predisposed to personality disorders? This report provides understanding into the biological basis of thinking and behavior in people with personality disorders, explains anatomic findings, and reviews therapeutic options.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”